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Abstract
Immunological tests for the diagnosis of tuberculosis (TB) have relied mostly on detection of immune markers in serum or release
of cytokines by mononuclear cells in vitro. These tests, although useful, sometimes fail to discriminate between active infection and
contact with mycobacteria or vaccination. TB is primarily a disease of the lung, and therefore identiﬁcation of immunological markers
in the respiratory tract will be more likely to reﬂect the infection status or disease activity. In this study, it is demonstrated that
active infection of mice with Mycobacterium bovis bacille Calmette-Gue´rin (BCG), but not exposure to heat-killed BCG, induced pro-
duction of interleukin-12 (IL-12), interferon-c (IFN-c) or soluble tumour necrosis factor receptors (sTNFRs) locally in the lungs, as
detected in bronchoalveolar lavage (BAL) ﬂuid. There was a strong correlation between bacterial growth in the lung and levels of
sTNFRs, and to some extent IL-12 and IFN-c, in BAL ﬂuid. Furthermore, sTNFR levels increased signiﬁcantly in BAL ﬂuid after reacti-
vation of controlled infection with dexamethasone, and this correlated with increased bacterial growth in the lungs. Finally, infection,
but not exposure to non-replicating mycobacteria, induced speciﬁc IgG and IgA in BAL ﬂuid. Elevated levels of all biomarkers mea-
sured were also detected in the serum, but correlation with infection was not as clear as in the case of BAL ﬂuid. Taken together,
the detection of sTNFRs and mycobacterium-speciﬁc antibodies, especially IgA, locally in the lungs could be used as immunological
markers for the diagnosis of TB.
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Introduction
It is estimated that between 5% to 10% of immunocompe-
tent individuals are susceptible to tuberculosis (TB), and of
these, 85% develop pulmonary disease [1] in the ﬁrst
2 years after exposure. Immunity to TB depends on several
factors, including cytokines, chemokines, antibodies, macro-
phages, neutrophils, several T-cell subsets, and speciﬁc pat-
terns of T-cell migration [2,3]. The infected host generates
a Th1 type of immune response, in which mycobacterial
antigen-speciﬁc T-lymphocytes are recruited to the lungs,
and play a signiﬁcant role in protection against Mycobacte-
rium tuberculosis infection [4]. Interferon-c (IFN-c) is consid-
ered to be an important correlate of protective immunity
against M. tuberculosis infection, and, together with other
cytokines such as interleukin-12 (IL-12) and tumor necrosis
factor (TNF), plays a critical role in the development of
protective granulomas and induction of antimycobacterial
activity in macrophages [2–5]. Even though the correlation
is less clear-cut, speciﬁc antibodies, particularly IgA, in
mucosal secretions have been related to protective immu-
nity against pulmonary infections [6].
Improvement in the currently available diagnostic tools
is of utmost importance for the control of the global TB
epidemic. In the vast majority of low-income and middle-
income countries, where TB is prevalent, diagnosis primarily
relies on the microscopic identiﬁcation of acid-fast bacilli in
unprocessed sputum smears. Although acid-fast staining is
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relatively quick, the sensitivity can be highly variable [7].
Although mycobacterial culture is the ultimate proof of
active M. tuberculosis infection, and is often used as a refer-
ence method for diagnosis, because of its high sensitivity and
speciﬁcity [8], it is slow and involves direct handling of live
bacteria. The tuberculin skin test is used widely in several
countries as the standard method for the diagnosis of latent
TB. The interpretation of this test, which is based on the
detection of a delayed-type hypersensitivity reaction to puri-
ﬁed protein derivative after intradermal injection, can, how-
ever, be affected by factors such as age, exposure to
environmental mycobacteria, or Mycobacterium bovis bacille
Calmette–Gue´rin (BCG) vaccination [9].
As compared with the traditional tuberculin skin test and
microscopy for acid-fast bacilli, newer IFN-c release assays
[10] and nucleic acid ampliﬁcation tests [11] lead to more
rapid detection of M. tuberculosis infection. However, the
sensitivity estimates for commercial nucleic acid ampliﬁcation
tests in respiratory specimens are highly variable [11]. In
addition, the infrastructure required to collect specimens,
deliver them to the correct laboratory and perform these
tests make it difﬁcult to establish in countries with severely
limited resources.
Until recently, researchers have looked mainly in serum
for identiﬁcation of speciﬁc mycobacterial antibodies as
markers of infection [12]. With regard to the use of cyto-
kines or cytokine receptors as surrogate markers of myco-
bacterial infection, levels have been assessed mainly in the
serum of TB patients [13,14]. Overall, serological methods
have been used with limited success. As TB is mainly a dis-
ease of the lungs, antibodies and cytokines detected locally
in the lungs and associated ﬂuids would be more likely to
reﬂect infection status.
In this study, we have followed the production of various
immunological parameters in mice, using BCG as the infec-
tious agent. We aimed to identify markers of cellular activa-
tion and speciﬁc mycobacterial antibodies locally in
bronchoalveolar lavage (BAL) ﬂuid and in serum that, in
combination or separately, might be indicative of active
mycobacterial infection. We demonstrated that active infec-
tion of mice, but not exposure to non-replicating mycobacte-
ria (heat-killed BCG (hk-BCG) or BCG lysate), resulted in
increased levels of IL-12, IFN-c and soluble TNF receptors
(sTNFRs) in the BAL ﬂuid. Moreover, infection, but not
exposure to non-replicating mycobacteria, induced produc-
tion of speciﬁc IgA antibodies in the respiratory tract that
were undetectable in serum. Despite the obvious differences,
mouse models of BCG infection have been extensively used,
and we discuss here the potential translation of our ﬁndings
to the diagnosis of human TB.
Materials and Methods
Mice
The studies were performed using 8–12-week-old female
BALB/c mice purchased from Taconic Europe, Denmark,
and housed in pathogen-free conditions. All animals
were kept at the Animal Department of the Arrhenius
Laboratories, Stockholm University, Sweden. Experiments
were performed in accordance with the guidelines of the
animal research ethics board at Stockholm University.
Bacteria
BCG (Pasteur strain), obtained from A. Williams, HPA, Salis-
bury, UK, was grown in Middlebrook 7H9 broth (Difco,
Sparks, MD, USA) with glycerol supplemented with
albumin–dextrose–catalase, at 37C, to the mid-log phase.
Aliquots were frozen in phosphate-buffered saline (PBS) with
toxiglycerol at )70C. Three vials picked randomly from the
stock were thawed, and serially diluted in plating buffer
(PBS with 0.05% Tween-80 (v/v)); CFUs were counted at
2–3 weeks after plating on Middlebrook 7H11 agar (Difco),
with glycerol and oleic acid–albumin–dextrose–catalase
enrichment.
To prepare hk-BCG, 107 CFU/mL of BCG were auto-
claved at 121C for 15 min, washed once, and resuspended
in sterile PBS before use. For the preparation of BCG
lysate, 107 CFU/mL bacteria were pelleted by spinning at
8000g, resuspended in 0.05% Tween-80 in PBS, and washed
twice. The bacteria were then resuspended in 5 mL of ice-
cold PBS and sonicated (Soniﬁer B12; Branson Sonic Power,
Danbury, CT, USA) on ice for 14 cycles of 1 min each, as
described by Power et al. [15]. The sonicated suspension
was spun at 12 000g for 30 min at 4C to remove particu-
late matter, and the supernatant containing soluble antigens
(referred to as BCG lysate) was collected and stored at
)20C. The protein concentration of the lysate was deter-
mined using the Bio-Rad protein assay reagent (Bio-Rad
Laboratories, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Soluble bovine serum albumin
fraction V was used as a protein standard.
Single mycobacterial antigens
The antigen 85 complex (Ag85) was obtained from
Colorado State University. The recombinant antigens
38 kDa, 19 kDa, and 16 kDa, commonly used in the
serodiagnosis of TB [16–18], were all obtained from
LIONEX Diagnostics & Therapeutics GmbH, Braunschweig,
Germany.
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Experimental infection or treatment with non-replicating
BCG, determination of CFUs, and reactivation of controlled
infection
Mice were infected intranasally with 107 CFU of live BCG, or
treated with 107 CFU of non-replicating BCG (BCG lysate or
hk-BCG) in 30 lL of PBS, or PBS alone as control. Mice were
anaesthetized with isoﬂuorane (Baxter Medical AB, Kista,
Sweden), and administration was carried out by inoculation of
15 lL per nostril given in two doses. Mice were allowed to
breathe the suspension into the lungs naturally [19]. At vari-
ous time-points, mice were killed by cervical dislocation.
Lungs, spleen and liver were removed aseptically, placed in
2 mL of plating buffer and homogenized in glass homogeniz-
ers. Serial dilutions of the organ homogenates were plated on
Middlebrook 7H11 agar plates with oleic acid–albumin–dex-
trose–catalase enrichment, and incubated at 37C. The num-
ber of CFUs was determined 2–3 weeks after plating.
Reactivation of controlled infection was performed as
described by Lowrie et al. [20], with some modiﬁcations. Mice
were injected intraperitoneally at week 10 after infection
(day 0) with 6 mg of dexamethasone (DXM) (Sigma, St Louis,
MO, USA) per kg body weight, and the treatment was
repeated at days 2, 4, and 6, giving a total of four doses.
Sample collection
Serum and BAL ﬂuid were collected from each group of
mice at different time-points. To obtain sera, mice were bled
from the tail vein, and serum was collected after centrifuga-
tion. BAL ﬂuid was obtained by ﬂushing 1.5 mL of PBS into
the lungs of the killed mice. All samples were kept at )20C
until use.
Cytokine and cytokine receptor detection assays
TNF and sTNFR ELISAs were performed using the commer-
cially available DuoSet ELISA Development Systems (R&D Sys-
tems Europe, Abingdon, UK), according to the manufacturer’s
recommendations, with slight modiﬁcations. Streptavidin con-
jugated to alkaline phosphatase (MABTECH, Nacka, Sweden)
was used instead of horseradish peroxidase, at a 1 : 1000 dilu-
tion. IL-12 (p70) and IFN-c ELISA was performed using com-
mercially available kits (MABTECH). The enzyme–substrate
reaction was developed using p-nitrophenyl phosphate
(Sigma). Optical density was read in a multiscan plate reader
(Anthos Labtech Instruments, Salzburg, Austria) at 405 nm.
On the basis of previous results, sample dilutions of BAL ﬂuid
started at 1 : 2, 1 : 5, 1 : 2, 1 : 5 and 1 : 50 for IFN-c, IL-12,
TNF, sTNFR1 and sTNFR2, respectively. Serum dilutions
started at 1 : 5, 1 : 10, 1 : 5, 1 : 40 and 1 : 100 for IFN-c,
IL-12, TNF, sTNFR1 and sTNFR2, respectively.
Detection of antibodies in serum and BAL ﬂuid
Antibodies in serum and BAL ﬂuid were analysed by ELISA as
described previously [6]. ELISA plates (high binding; Costar,
Corning, NY, USA) were coated with either BCG lysate
(20 lg/mL) or Ag85, 38 kDa, 19 kDa or 16 kDa (2 lg/mL) in
carbonate–bicarbonate buffer (pH 9.6) overnight at room
temperature (RT). After washing, diluted samples were incu-
bated overnight at RT. Plates were then washed and incubated
for 2 h at RT with alkaline phosphatase-labelled goat anti-
mouse IgG or IgA (Southern Biotech, Birmingham, AL, USA),
and the enzyme–substrate reaction was developed using
p-nitrophenyl phosphate as substrate. Optical density was
measured in a multiscan reader at 405 nm. Non-speciﬁc
antibodies were determined in parallel, using bovine serum
albumin fraction V as an unrelated antigen, and these values
were deducted from those obtained for speciﬁc anti-BCG anti-
bodies. For the detection of antibodies in BAL ﬂuid or serum,
single sample dilutions were chosen on the basis of initial
results, starting from 1 : 5 (BAL ﬂuid) and 1 : 100 (serum).
Statistical analysis
One-way analysis of variance (ANOVA) with Bonferroni
post hoc tests was used to compare bacterial growth in the
lungs or cytokine and soluble receptor levels in BAL ﬂuid,
taking day 3 as the reference point. Spearman’s rank correla-
tion was used to establish the correlation between bacterial
burden and cytokine or soluble cytokine receptor levels.
Data are presented as the mean value ± standard deviation,
and are considered to be signiﬁcant when *p <0.05. All
analyses were performed with SigmaStats software Systat
Software Inc., San Jose, CA, USA.
Results
Intranasal infection, but not treatment of mice with non-
replicating BCG, induces elevated levels of IL-12, IFN-c and
sTNFRs in the lungs
TNF, IL-12 and IFN-c are essential components of the protec-
tive immune response against mycobacterial infection, and ele-
vated levels of these cytokines in the lungs, the principal
organ involved during M. tuberculosis infection, could be indica-
tive of disease activity. To assess this, BAL ﬂuid from mice
infected intranasally with BCG or treated with non-replicating
BCG was collected at different time-points and analysed for
IL-12, IFN-c and TNF. Bacterial load was quantiﬁed in lung,
spleen and liver homogenates (Fig. 1a).
Live, but not non-replicating, BCG induced production of
IL-12 and IFN-c in the lungs (Fig. 1b–c). The amount of IL-12
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FIG. 1. Intranasal infection, but not treatment of mice with non-replicating BCG, induces elevated levels of IL-12 and IFN-c, STNFRs in the
lungs. Mice were infected intranasally with 107 CFU of BCG or treated with corresponding amounts of BCG lysate or heat-killed (BCG)
(hk-BCG), and control mice were treated with PBS. Organs (lung, spleen, and liver) and BAL ﬂuid were collected at day 3, weeks 1, 3, 5 and 9
after infection or treatment with hk-BCG, at day 3, weeks 1, 3 and 5 after treatment with BCG lysate, or at day 3 and week 9 for PBS-treated
mice. Serial dilutions of lung, spleen and liver were plated on Middlebrook 7H11 agar, and bacterial loads were determined 2–3 weeks after
plating (a). Levels of IL-12 (b), IFN-c (c), sTNFR1 and sTNFR2 (d, e) in BAL ﬂuid were measured with standard ELISA kits, using single sample
dilutions of 1 : 5, 1 : 2, 1 : 5 and 1 : 50; mean concentrations are expressed as pg/mL. Results are expressed as mean CFU · 103 (a) and concen-
trations ± standard deviation (b–e) from four mice per group. The results shown are representative of three different experiments. *p <0.05,
**p <0.01 and ***p <0.001 vs. D3.
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detected in BAL ﬂuid progressively increased during infection
to week 3 (p <0.001), and declined signiﬁcantly by week 9.
There was a positive relationship, but a weak correlation
(r 0.48), between IL-12 levels in BAL ﬂuid and bacterial
growth in the lungs (Fig. 1a). The highest level of IFN-c in
BAL ﬂuid (week 5), unlike that of IL-12 (week 3), did not
exactly coincide with the peak bacterial growth in the lungs
(week 3), but was indicative of active infection. In contrast
to IL-12 or IFN-c, minimal amounts of TNF were detected
at all time-points (data not shown).
As TNF was barely detectable in BAL ﬂuid, we reasoned
that elevated levels of sTNFRs could result in TNF neutral-
ization [21]. To assess this, we measured the levels of
sTNFR1 and sTNFR2. As in the case of IL-12 and IFN-c, live,
but not non-replicating BCG induced increased levels of
sTNFRs in the lungs, as detected in BAL ﬂuid (Fig. 1d–e).
There was a strong correlation between levels of sTNFR1
and sTNFR2 in BAL ﬂuid (r 0.7 and r 0.68, respectively) and
bacterial growth in the lungs. As compared with the lungs,
there was signiﬁcantly lower infectivity of the spleen or liver
after intranasal infection of mice with BCG (Fig. 1a). Similar
results were obtained in animals infected intravenously, even
though bacterial growth in the spleen and liver increased
(data not shown).
Elevated levels of IL-12 and sTNFRs in serum are more
indicative of exposure to mycobacterial antigens than active
infection
Peripheral blood is used for assessing the state of infection
in several diseases. To determine whether serum levels of
IL-12 or sTNFRs could be used in the same way as BAL ﬂuid
levels to predict an ongoing mycobacterial infection, sera col-
lected from the tail vein at the time-points indicated above
were analysed for the presence of cytokines. Increased levels
of IL-12 and sTNFRs were found in serum, not only after
infection, but also after treatment of mice with non-replicat-
ing BCG (Fig. 2a–c). There was no direct relationship
between IL-12 or sTNFR level and bacterial growth (Fig. 1a)
in the lungs, spleen, or liver. In these experiments, TNF and
IFN-c were undetectable in serum. These results suggest that
the detection of cytokines or soluble receptors in serum
may not be reﬂective of bacterial growth in the lungs, and
therefore may not be reliable for prediction of an ongoing
mycobacterial infection.
Reactivation of mycobacterial infection results in elevated
levels of sTNFRs in BAL ﬂuid
During the course of their lives, 5–10% of people latently
infected with M. tuberculosis experience reactivation of their
infection as a consequence of immunosuppression, resulting
in increased bacterial growth in the lungs and other organs.
In animal experiments, reactivation of controlled mycobacte-
rial infection has been achieved by the administration of
DXM [20], a corticosteroid that suppresses the effector
functions of T-cells, which are central to the control of infec-
tion. To determine whether increased bacterial growth in
the lungs would result in elevated levels of sTNFRs in BAL
ﬂuid, previously infected mice, that have controlled their
infection (week 10 after intranasal infection), were treated
with DXM as described above, and BAL ﬂuid and serum
were analysed for the presence of sTNFRs.
Administration of DXM resulted in increased bacterial
growth in the lungs (Fig. 3a) by week 2 after treatment.
There was also a slight but non-signiﬁcant increase in bacte-
rial load in the spleen and liver (data not shown). Soluble
TNFR levels increased signiﬁcantly in BAL ﬂuid 2 weeks after
DXM treatment (Fig. 3b–c), and this correlated strongly with
bacterial growth in the lungs (r 0.9 and r 0.7 for sTNFR1 and
sTNFR2, respectively). In contrast, sTNFR levels in serum
after DXM treatment were comparable with those in
untreated mice (data not shown). These results conﬁrm our
observation that sTNFR levels in BAL ﬂuid correlate with
bacterial growth in the lungs, and higher sTNFR levels may
be indicative of an ongoing mycobacterial infection.
Mycobacterium-speciﬁc antibodies can be detected in BAL
ﬂuid and serum, but association with active infection in the
lungs is more clearly correlated with BAL ﬂuid antibodies
Thus far, our results have demonstrated a correlation
between mycobacterial growth in the lungs and sTNFR levels
in the lung microenvironment. Although there was a good
correlation between sTNFR levels and active infection, this
parameter is generally a marker of cell activation, and is not
speciﬁc for mycobacterial infection. To conﬁrm that infection
was caused by mycobacteria, we analysed BAL ﬂuid and
serum for the presence of speciﬁc IgG and IgA antibodies,
using BCG lysate as antigen. Only infected mice produced
detectable levels of IgG antibodies in BAL ﬂuid and serum
(Fig. 4a–b), and the levels increased over time. BCG-speciﬁc
IgA was detected in BAL ﬂuid, but not in serum, and had
similar kinetics to IgG (Fig. 4a).
Next, we determined whether detection of antibodies to
single mycobacterial antigens in BAL ﬂuid and serum could
be used to predict an ongoing infection. As was found for
BCG lysate, only active infection resulted in production of
antigen-speciﬁc IgG or IgA in BAL ﬂuid (Fig. 4c–d). In the
serum, IgG but not IgA to single antigens was detectable
after infection with BCG (data not shown). However, mod-
erate amounts of IgG were detectable in sera obtained from
mice treated with non-replicating BCG (Fig. 4e), indicating
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that serum levels may not be absolutely correlated with
active infection. Overall, these data suggest that detection of
antibodies to multiple or single mycobacterial antigens in
BAL ﬂuid, especially IgA, may be predictive of an ongoing
infection in the lungs.
Discussion
The biological complexity of M. tuberculosis infection means
that the use of a single immunological marker to predict of
infection or disease activity would probably have limited diag-
nostic value, and analysis of several biomarkers would offer
the possibility of improved diagnosis. In this study, we have
assessed elements of the Th1 immune proﬁle together with
speciﬁc antibodies in the evaluation of the status of mycobac-
terial infection in mice. We have also demonstrated that, in
TB, evaluation of local immune responses in the respiratory
tract is more reliable than serum studies.
Over the years, the majority of studies that have investi-
gated cytokines or their soluble receptors as markers of
active disease in TB patients have looked mainly at the
serum [13,14]. However, M. tuberculosis infection occurs
more frequently via the respiratory tract, and currently there
is a belief that in TB, as well as in other lung diseases, the
markers of disease activity need to be measured locally in
the lungs, and not in peripheral blood. In the present study,
elevated levels of IL-12 or sTNFRs in serum were associated
with exposure to mycobacterial antigens in general, and not
exclusively to active infection. In contrast, elevated levels of
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FIG. 2. Elevated levels of IL-12 and sTNFRs in serum are more indicative of exposure to mycobacterial antigens than of active infection. Sera
from mice infected with live or non-replicating BCG as described in Fig. 1 were analysed for the presence of IL-12 (a), sTNFR1 (b) and sTNFR2
(c), with standard ELISA kits, using single sample dilutions of 1 : 10, 1 : 40 and 1 : 100; mean concentrations are expressed as pg/mL. Results are
expressed as mean concentration ± standard deviation (a–c) from four mice per group. The results shown are representative of three different
experiments. hk-BCG, heat-killed BCG; PBS, phosphate-buffered saline.
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IL-12 and IFN-c, or the shedding of sTNFRs, in BAL ﬂuid
depended on the infection status. Also, in humans, several
studies have directly demonstrated a relationship between
cytokine production in the lungs and active TB, usually based
on cytokine release by mononuclear cells at the site of infec-
tion [22,23]. However, in these studies, a TB patient was
deﬁned as any patient with a chest radiograph suggestive of
TB, regardless of human immunodeﬁciency virus status. Thus,
a possible contribution from some other co-infections could
not be entirely excluded [24].
To conﬁrm that the infective agent was BCG, we analysed
mycobacterium-speciﬁc antibodies in BAL ﬂuid and serum after
active infection of mice, or treatment with non-replicating
BCG lysate or single mycobacterial antigens were used for
detection of antibodies. The higher levels of antibodies found
in both BAL ﬂuid and serum at week 9 after BCG infection,
as compared with the early time-points, were expected. In
contrast, non-replicating antigens would need continuous
priming and/or help from relevant adjuvants to be optimally
immunogenic. This may explain the inability of the non-
replicating BCG administered as single doses to induce
detectable antibodies in BAL ﬂuid. Nevertheless, detectable
levels of speciﬁc IgG were measured in serum of mice
treated with non-replicating BCG. One explanation could be
that the amounts of the single antigens in the coated
plates were higher when they were used alone than when
BAL  
BCG (–DXM)
BCG (+DXM)
25 
30 Bacterial load 
** 
* 
CF
U
 ×
 1
03
 
0 
5 
10 
15 
20 
Week 9  Week 11  Week 12  Week 13  
DXM 
(pg
/m
L)
 
sTNFR1 
400 
600 
800 
1000 
1200 
Week 9  Week 11  Week 12  Week 13  
** 
* 
DXM 
(pg
/m
L)
 
Week 9  Week 11  Week 12  Week 13  
** 
sTNFR2 
1000 
2000 
3000 
4000 
5000 
6000 
7000 
8000 
* 
DXM 
(a) (b) 
(c) 
FIG. 3. Reactivation of mycobacterial infection results in elevated levels of sTNFRs in BAL ﬂuid. Mice with controlled BCG growth in the lungs
at week 10 after intranasal infection with 107 CFU of BCG were injected intraperitoneally with 6 mg of dexamethasone (DXM) per kilogram
body weight every other day for a total of four injections. Organs (lung, spleen, and liver) and BAL ﬂuid were collected at weeks 1–3 after
DXM treatment. Serial dilutions of lungs were plated on Middlebrook 7H11 agar, and bacterial loads were determined 2–3 weeks after plating
(a). BAL ﬂuid was assayed as described above for detection of sTNFRs; mean concentrations expressed as pg/mL (b–c). Results are expressed
as mean CFU · 103 (a) or concentration ± standard deviation (b–c) from four mice per group. The results shown are representative of three
different experiments. *p <0.05 and **p <0.01 vs. w11.
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plates were coated with the whole lysate, when competi-
tion with other molecules for binding would obviously be
greater.
In our study, IgA was detectable only in BAL ﬂuid. IgA is
the major immunoglobulin in mucosal secretions, and our
group [6] and others [25] have demonstrated the induction
of IgA in mucosal secretions after intranasal immunization
with mycobacterial antigens, or infection with mycobacteria,
respectively. The four antigens selected have been commonly
used for the serodiagnosis of TB [12,16–18]. In contrast to
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FIG. 4. Intranasal infection, but not treatment of mice with non-replicating BCG, results in production of BCG or antigen-speciﬁc antibodies in
BAL ﬂuid and serum. Mice were infected intranasally with 107 CFU of BCG or treated with 107 CFU of non-replicating BCG, and BAL ﬂuid and
sera were collected as above. (a) Microtitre plates were coated with 20 mg/L of BCG lysate as antigen ON in bicarbonate buffer (pH 9.6), and
the amounts of BCG-speciﬁc antibodies were measured in BAL ﬂuid and serum, using single sample dilutions of 1 : 25 and 1 : 50 for IgA and
IgG in BAL ﬂuid, and 1 : 2000 for IgG in serum. (b) Ag85, 38 kDa, 19 kDa or 16 kDa (2 mg/L) were used singly as coating antigens, as described
for detection of antigen-speciﬁc antibodies in BAL ﬂuid (c, d) and serum (e). Optical density (OD) was read at 405 nm, and the results are
expressed as mean OD from four mice per group. The results shown are representative of three different experiments.
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Ag85, 38 kDa or 19 kDa, lower amounts of anti-16 kDa anti-
bodies were detectable in BAL ﬂuid and serum. The 16 kDa
antigen is a cytosolic regulatory protein speciﬁc to the
M. tuberculosis complex and is expressed during latency [26].
A systematic analysis of humoral immune responses of TB
patients has shown that the proﬁles of antigenic proteins of
M. tuberculosis recognized by antibodies differ at different
stages of infection and disease progression [27]. This sug-
gests that an accurate diagnostic test for TB will need to be
based on a combination of antigens.
It is clear that measurement of immune markers in BAL
ﬂuid may be technically demanding in resource-limited set-
tings. Therefore, a methodology to perform similar studies in
other mucosal secretions such as saliva would be rapid, sim-
ple, inexpensive and non-invasive in comparison with obtain-
ing BAL ﬂuid. This may be possible, because in previous
studies we have demonstrated the presence of speciﬁc anti-
bodies both in BAL ﬂuid and in saliva after intranasal immuni-
zation with mycobacterial antigens [28]. Moreover, some
human studies have revealed IgA antibodies speciﬁc for the
38 kDa mycobacterial antigen in the saliva of children aged
1–15 years [29]. For this reason, we are working to improve
our detection assays in saliva. In conclusion, detection of a
tailored combination of mycobacterium-speciﬁc antibodies
and cellular markers in the respiratory tract will be useful
for the immunodiagnosis of TB, and may help in the predic-
tion of the clinical course of disease.
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